DATATRAK Awarded Three Phase III Studies

DATATRAK Awarded Three Phase III Studies
October 11th, 2010 - Filed under: Press Releases.

CLEVELAND, Oct. 11 /PRNewswire/ - DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of an Enterprise Agreement for three new Phase III oncology studies with an existing client. These multi-center studies will be deployed utilizing the unified DATATRAK eClinicalTM platform.

"DATATRAK is pleased to have three new oncology studies running on our unified eClinical platform. With over 1 million new patients diagnosed with cancer each year and less than 5% of them being enrolled in clinical trials, we are excited to participate in trials with innovative compounds that hold the promise of a cure," said Laurence P. Birch, DATATRAK's Chairman and CEO. "Our knowledge of the complex and unique requirements related to oncology trials has been built into DATATRAK eClinicalTM; these oncology-specific solutions within our unified platform provide our clients with the necessary tools to deliver clinical trials with safety, simplicity and speed."

About DATATRAK International, Inc.
DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONETM, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinicalTM software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 67 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas. For more information, visit www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's quarterly report filed with the Pink OTC Markets on August 13, 2010 announcing its results for the three-month period ending June 30, 2010. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

CONTACT:
Lisa Pahl, Director Marketing, DATATRAK International, Inc., +1-979-393-9025

 

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.